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Abstract 
 
Treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors is 
associated with a high response rate. However, a subset of melanoma patients with intrinsic and 
acquired resistance is insensitive to these therapeutics. Thus, to improve melanoma therapy, 
new drug candidates with novel mechanisms of action need to be identified. The objective of 
this study was to identify an anti-melanoma agent and to identify the mechanisms by which it 
inhibits tumor cell growth. 
Chapter I describes the identification of an anti-melanoma compound, CH5552074, and its 
mechanisms of action. In order to identify novel anti-melanoma compounds, a chemical library 
was screened against a melanoma cell line panel. CH5552074 showed remarkable cell growth 
inhibition activity in melanoma cell lines. To investigate the mechanisms of action of 
CH5552074, I conducted an Ingenuity Pathway Analysis (IPA) correlating data on compound 
sensitivity and gene expression profiles of each cell line. The IPA results suggested that 
CH5552074-sensitive cell lines had activated microphthalmia-associated transcription factor 
(MITF), which plays a critical role in melanoma progression. Further in vitro studies using the 
melanoma cell line SK-MEL-5 revealed that suppression of MITF with siRNA resulted in cell 
growth inhibition. These results showed that CH5552074 inhibited cell growth by reducing the 
protein expression of MITF. These data support the therapeutic potential of CH5552074 as an 
anti-melanoma agent with capacity to downregulate MITF protein expression levels. 
Chapter II provides information on an orally available compound, CH6868398, which was 
identified and evaluated for in vivo efficacy alone and in combination with a BRAF inhibitor, 
PLX4720. CH6868398 has a novel chemical structure and arrests MITF protein expression in 
melanoma cells. It inhibited the growth of MITF-dependent melanoma cells both with and 
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without BRAF mutation and exhibited anti-tumor effects in a melanoma xenograft model. 
Because selective BRAF inhibitors are standard therapeutics for BRAF-mutated melanoma, I 
investigated the effect of CH6868398 in combination with PLX4720 on cell growth inhibition. 
The addition of CH6868398 enhanced the growth inhibition activity of PLX4720 in melanoma 
cell lines. Furthermore, the combination of CH6868398 and PLX4720 efficiently suppressed 
MITF protein expression and enhanced the cleavage of Caspase 3 and poly (ADP-ribose) 
polymerase (PARP) in melanoma cell lines. 
In conclusion, I identified some anti-melanoma agents with a novel mechanism of action, 
particularly MITF suppression. CH6868398 inhibited tumor growth in a xenograft model and 
improved the sensitivity of melanoma cells to a BRAF inhibitor. These data suggest the 
therapeutic potential of CH6868398 as an anti-melanoma agent that reduces MITF protein 
expression in combination with BRAF inhibitors. 
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Abbreviations 
 
ATN1:  atrophin-1 
CTLA-4: cytotoxic T-lymphocyte associated protein 4 
DMSO: dimethyl sulfoxide 
FDA:  Food and Drug Administration 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
GC-RMA: guanine-cytosine robust multiarray analysis 
HDAC: histone deacetylase 
HIV1:  human immunodeficiency virus type 1 
IPA:  Ingenuity Pathway Analysis 
MAPK: mitogen-activated protein kinase 
MHC:  major histocompatibility complex 
MEK:  MAPK/ERK kinase 
MITF:  microphthalmia-associated transcription factor 
PARP:  poly (ADP-ribose) polymerase 
PAX3:  paired box gene 3 
PCR:  polymerase chain reaction 
PD-1:  programmed cell death protein 1 
RT-PCR: real-time PCR 
PI3K:  phosphoinositide 3-kinase 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SLC45A2: solute carrier family 45 member 2 
SOX10: SRY-related HMG-box 10 
SUMO: small ubiquitin-like modifier 
TMB:  tumor mutation burden 
TRIM24: tripartite motif-containing 24 
TRPM1: transient receptor potential cation channel, subfamily M, member 1 
UV:  ultraviolet 
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General Introduction 
 
Melanoma is a highly aggressive cancer that tends to metastasize to other parts of the body. 
The estimated numbers of new melanoma cases and deaths in Europe are 144.2 per 100,000 
and 27.1 per 100,000, respectively [1]. Melanoma often arises from melanocytes in the skin 
that are frequently exposed to sunlight. Increased exposure to ultraviolet (UV) light is one of 
the causative risk factors for melanoma. UV radiation directly affects nucleotide base pairing 
in DNA, especially in pyrimidine bases which are especially vulnerable to chemical change by 
absorption of UV energy [2]. DNA damage induces cellular responses that result in several 
different outcomes including DNA repair, cell cycle arrest, modulation of DNA replication 
dynamics, altered gene expression, and cell death. When DNA repair processes fail, 
accumulated DNA damage in melanocytes induces melanoma. 
For stage I and II melanoma, surgical resection is the standard treatment and improves 
long-term survival with a 5-year survival rate of over 90% [3]. On the other hand, stage III 
melanoma is highly recurrent even after locoregional resection and has a poor prognosis due to 
metastases. For metastatic melanoma, the standard treatment is pharmacological therapy. 
Currently, we have a wide range of treatment options such as chemotherapy with dacarbazine, 
BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors. Dacarbazine was 
considered as a gold standard therapy for metastatic melanoma until a BRAF inhibitor and an 
anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody were approved by the 
Food and Drug Administration (FDA) in 2011. The median survival time was 7.7 months for 
advanced metastatic melanoma patients treated with dacarbazine, which was approved by FDA 
in 1975 [4]. Dacarbazine is an alkylating chemotherapy drug which causes DNA modification. 
In order to achieve better responses with dacarbazine, combination treatment of dacarbazine 
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with other chemotherapies was evaluated. However these combination treatments induced high 
toxicity. In parallel to the work on dacarbazine improvement, genomic analysis of melanoma 
has been conducted. 
Sequencing analysis focusing on the genes of the mitogen-activated protein kinase 
(MAPK) pathway revealed that BRAF somatic missense mutations are observed in 66% of 
malignant melanoma cases [5]. All mutations are located within the kinase domain and improve 
BRAF activity. Furthermore, mutated BRAF has oncogenic activity and can transform NIH3T3 
cells. These findings led to the development of BRAF inhibitors as anti-melanoma drugs. A 
BRAF inhibitor, vemurafenib, is an orally available and selective inhibitor of the BRAF V600E 
mutant and was approved by the FDA for the treatment of patients with nonresectable or 
metastatic melanoma in 2011. A phase 3 study (BRIM-3) comparing vemurafenib to 
dacarbazine treatment in patients with previously untreated metastatic melanoma with BRAF 
V600E mutation showed that the overall survival rate after 6 months was 84% in the patients 
treated with vemurafenib and 64% in the patients treated with dacarbazine [6]. However, 
disease progression was observed in 50% of patients treated with BRAF inhibitors 
approximately 6 months after treatment initiation [6-8]. Resistance to MAPK pathway 
inhibitors is triggered by several mechanisms, such as alternative splicing of BRAF, BRAF 
amplification, RAS mutations, and activation of the phosphoinositide 3-kinase (PI3K)-AKT 
pathway [9-13]. One of the factors suggested as a key driver that makes melanomas resistant to 
MAPK pathway-targeted inhibitors is the upregulation of MITF [13-15]. 
Another genomic feature of malignant melanoma is a high tumor mutation burden (TMB). 
Mutation analysis of 7,042 primary cancers in 30 different tumor types revealed that malignant 
melanoma exhibited the highest mutation prevalence [16]. The high TMB in malignant 
melanoma triggers the increased neoantigen presentation on major histocompatibility complex 
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(MHC) molecules and induces immune response. Therefore, melanoma is thought to be 
sensitive to immune checkpoint inhibitor treatment. Indeed, immune checkpoint inhibitor 
treatment has shown clinical efficacy in patients with malignant melanoma. Ipilimumab binds 
CTLA-4, an immune checkpoint protein that downregulates pathways responsible for T cell 
activation and was approved by FDA in 2011. In a phase 3 study, ipilimumab improved the 
overall survival of patients previously treated metastatic melanoma [17]. Additionally, 
combination treatment of ipilimumab and dacarbazine improved the overall survival of patients 
with previously untreated metastatic melanoma [18]. The second approved immune checkpoint 
inhibitor in melanoma by FDA is pembrolizumab. Pembrolizumab is a humanized 
immunoglobulin G4 mAb targeting programmed cell death protein 1 (PD-1) molecule. In a 
phase 3 clinical study (Keynote-006 trial), pembrolizumab prolonged the progression-free 
survival and overall survival and had less high-grade toxicity when compared with ipilimumab 
in patients with advanced melanoma [19]. Furthermore, combination treatment of ipilimumab 
and nivolumab, an anti-PD-1 antibody, improved the median overall survival when compared 
with the treatment of ipilimumab alone [20]. Although combination treatment of anti-CTLA-4 
antibody or anti-PD-1 antibody improved the efficacy compared with the monotherapies, 
disease progression was observed in 50% of patients 11.5 months after treatment initiation [20]. 
Treatment for metastatic melanoma has been improved by BRAF inhibitors and immune 
checkpoint inhibitors, but a subset of the patients is still insensitive to them. Therefore, novel 
drugs with other mechanisms of action are required. In order to explore novel anti-melanoma 
therapeutics, I screened a chemical library against a melanoma cell line panel and identified 
CH5552074, as described in Chapter I. Examination of the action mechanisms of the compound 
suggested that MITF suppression is the potential mechanism for melanoma cell growth 
inhibition. 
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MITF is a key transcription factor that is expressed in a melanocytic lineage and has a key 
role in melanocyte development, differentiation, and transformation [21, 22]. MITF activity is 
regulated by its upstream activators and suppressors and modulated at transcriptional, post-
transcriptional, and post-translational levels [23]. In melanoma cells, genetic alterations in 
MITF are observed. Quantitative polymerase chain reaction (PCR) analysis revealed that MITF 
amplification was observed in 10% of primary cutaneous melanoma and 21% of metastatic 
melanoma cases [24]. Growth of melanoma cells with MITF copy gain was inhibited following 
MITF suppression with dominant-negative MITF introduction [24]. Genetic alterations in 
MITF also include single base mutation. A germline missense mutation in MITF (E318K) is 
observed at a significantly higher frequency in genetically enriched melanoma patients than in 
the controls [25, 26]. Because codon 318 in MITF is located in a small ubiquitin-like modifier 
(SUMO) consensus site, MITF E318K mutation severely impairs SUMOylation of MITF and 
enhances MITF function. Additionally, MITF activation is observed in melanoma cells resistant 
to BRAF inhibitors [13, 14]. This observation suggests that the combination of BRAF inhibition 
and MITF suppression exhibits enhanced growth inhibitory effects against melanoma cells. 
Therefore, I examined melanoma cell growth inhibition activity of the combination treatment 
of the BRAF inhibitor, PLX4720, and the MITF suppressor, CH6868398, as described in 
Chapter II. 
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Chapter I: MITF suppression by CH5552074 inhibits cell growth in 
melanoma cells 
 
1. Introduction 
 
Malignant melanoma is an aggressive type of cancer and has a poor prognosis for advanced 
disease. Selective molecular targeted therapy that blocks BRAF and MEK improves survival in 
melanoma patients with BRAF mutation remarkably [6, 27, 28], but the therapy rarely shows 
durable response due to various resistant mechanisms [13, 14]. In another therapeutic approach, 
antibodies that block CTLA-4 and PD-1 significantly improve overall survival in patients with 
melanoma [17, 29-31]. However, these immune checkpoint inhibitors are effective only in 
limited patients. Therefore, there is room to develop therapeutics with novel mechanisms of 
action on malignant melanomas. 
A potential mechanism for melanoma therapy is to target MITF, which is expressed in 
melanomas and has been shown by various research studies to be a transcription factor with a 
critical role in melanocyte development and transformation [21, 22]. MITF activity induces cell 
proliferation and MITF expression levels are increased by mutant BRAF, which triggers 
constitutive hyperactivation of MEK/ERK signaling in melanoma cells [32]. Additionally, gene 
amplification of MITF is observed in up to 20% of melanomas [24], and MITF activation is 
observed in melanomas resistant to BRAF inhibitors [13, 14]. Finally, the finding that inhibition 
of MITF mRNA reduces cell growth in melanoma cells also supports the potential of MITF as 
a target for melanoma therapy [24]. 
In this study, I identified CH5552074 as an anti-melanoma agent in a skin cancer cell panel 
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and then used IPA to investigate the mode of action by which it induced inhibition of cell growth. 
Following the results of the IPA analyses, I also evaluated the MITF-dependent potential of this 
compound to induce cell growth inhibition in melanoma cells. 
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2. Materials and Methods 
 
2.1. Reagents 
CH5552074 was synthesized at Chugai Pharmaceutical Co., Ltd (Kanagawa, Japan). 
Dharmacon ON-TARGETplus siRNA was purchased from GE Healthcare (Buckinghamshire, 
UK). 
 
2.2. Cell cultures 
SK-MEL-5, SK-MEL-1, SK-MEL-28, A-431, SK-MEL-2, HMCB, and C32 cells were 
obtained from the American Type Culture Collection (Manassas, VA, USA). A375 cells were 
purchased from DS Pharma Biomedical Co., Ltd (Osaka, Japan). A2058 cells were purchased 
from Health Science Research Resources Bank (Osaka, Japan). SK-MEL-30 cells were 
obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, 
Germany). All cell lines were cultured according to the supplier’s instructions. 
 
2.3. In vitro cell growth assay 
The cells were seeded into 96-well plates containing various concentrations of the 
compound or siRNA with Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA) 
and were incubated for 4 days at 37°C. The absorbance at 450 nm or the chemiluminescent 
signal for the cell viability was measured with a Microplate-Reader iMark (Bio-Rad 
Laboratories, Hercules, CA, USA) after addition of a Cell Counting Kit-8 solution (Dojindo 
Laboratories, Kumamoto, Japan) or with an EnVision Multilabel Plate Reader (PerkinElmer, 
Waltham, MA, USA) after addition of a Cell Titer-Glo luminescence cell viability kit (Promega, 
Madison, WI, USA), respectively. Anti-proliferative activity was calculated using the formula 
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(1−T/C) × 100 (%), where T represents the measured values of reagent-treated cells and C 
represents that of untreated control cells. 
For real-time analysis, IncuCyte Zoom System (Essen Biosciences, Ann Arbor, MI, USA) 
was utilized. The cells were seeded into 96-well plates and treated with various concentrations 
of CH5552074. The culture plate was incubated in an IncuCyte Zoom System in a cell culture 
incubator. Cell images were captured in 2 fields per well every 4 hours following treatment with 
CH5552074. The occupied area (% confluence) was determined using IncuCyte Zoom software 
(Essen Biosciences). 
 
2.4. Microarray analysis 
Total RNA was extracted from cells with an RNeasy Mini Kit (Qiagen, Germantown, MD, 
USA) and was reverse transcribed, labeled, and hybridized to Human Genome U133 Plus 2.0 
arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. The 
gene expression level for each probe was calculated utilizing the guanine-cytosine robust 
multiarray analysis (GC-RMA) algorithm [33]. 
 
2.5. IPA analysis 
IPA software [34] was used to identify upstream pathways that might affect CH5552074 
sensitivity. Correlation factors of the probes were calculated from the natural logarithmic 
expression levels of each probe in a microarray analysis of 10 cell lines and natural logarithmic 
IC50 values calculated in an in vitro cell growth assay of the cell lines treated with CH5552074. 
To remove genes that were expressed in the 10 cell lines at almost the same level, probes with 
a natural logarithmic expression range of <2 across samples were filtered out. The gene set for 
IPA consisted of genes for which the correlation factors of the corresponding probes were >0.7 
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or <−0.7. The gene set was analyzed through IPA core analysis and an upstream analysis. 
 
2.6. Western blot analysis 
Cells were lysed in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA) 
containing protease inhibitors and phosphatase inhibitors. Western blot analysis was performed 
as described previously [35]. Primary antibodies were used for MITF and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Dallas, TX, USA). Signals 
were developed using Pierce Western Blotting Substrate Plus (Thermo Scientific, Rockford, IL) 
and detected with LAS-4000 (Fujifilm, Tokyo, Japan). 
 
2.7. Gene expression analysis with Taqman probes 
Total RNA was isolated from cells with an RNeasy Mini Kit (Qiagen). For real-time PCR 
(RT-PCR) analysis, the isolated RNA and TaqMan Fast Virus 1-Step Master Mix (Applied 
Biosystems, Foster City, CA, USA) were used. The following Taqman probes (Applied 
Biosystems) were used: MITF (Hs01117294_m1) and GAPDH (4325792). Reactions were run 
on a ViiA 7 Real-Time PCR System (Applied Biosystems). The gene expression levels of MITF 
were measured against the housekeeper gene GAPDH and determined utilizing ViiA 7 Software 
(Applied Biosystems). 
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3. Results 
 
3.1. Identification of CH5552074 and its in vitro cell growth inhibition activity 
To identify an anti-melanoma agent, I screened a chemical library against multiple 
melanoma cell lines and A-431 epidermal carcinoma in skin and found a lead compound, 
CH5552074, which had a novel chemical structure (Fig. 1-1a). In an in vitro cell growth 
inhibition assay, CH5552074 exhibited cell growth inhibition activity against the melanoma 
cell lines (Fig. 1-1b). Additionally, the in vitro cell growth inhibition activity of CH5552074 
was examined to determine the sensitivity in melanoma cell lines with different BRAF mutation 
status: BRAF V600E mutation (SK-MEL-5, A375, SK-MEL-1, SK-MEL-28, A2058, and C32 
cells) and wild-type BRAF (SK-MEL-30, A-431, SK-MEL-2, and HMCB cells). The IC50 
values of CH5552074 were 0.24–1.2 μM in melanoma cell lines and were independent of BRAF 
mutation status (Table 1-1). These data suggested that CH5552074 had a different mode of 
action from BRAF inhibitors. 
 
3.2. MITF modulation as a candidate for the mode of action of CH5552074 
CH5552074 had cell growth inhibition activity against the melanoma and epidermal 
carcinoma cell lines, but the mode of action by which the compound showed this activity was 
unclear. In order to investigate the mode of action, I performed IPA of a gene set that correlated 
with CH5552074 sensitivity in each cell line. First, the mRNA expression profile in each cell 
line was examined by microarray analysis. I then calculated the correlation factors of each probe 
using its expression level and the IC50 values in each cell line and identified the 107 genes for 
which correlation factors of the corresponding probes were >0.7 or <−0.7 (Table 1-2). In order 
to determine an upstream regulator that is activated or inactivated in CH5552074-sensitive cell 
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lines, 107 genes were subjected to core and upstream analysis in IPA. These analyses suggested 
MITF, atrophin-1 (ATN1), forskolin, GSK0660, and tripartite motif-containing 24 (TRIM24) 
as candidates for upstream regulators of CH5552074 sensitivity in melanoma cells (Table 1-3). 
I focused on MITF as a regulator of CH5552074 sensitivity because it has an extremely low p-
value within these candidates, which represents the highest probability. When mRNA 
expression levels of MITF and genes regulated by MITF (transient receptor potential cation 
channel, subfamily M, member 1 (TRPM1) [36] and solute carrier family 45 member 2 
(SLC45A2) [37]) were assessed, they had a tendency to be higher in CH5552074-sensitive cell 
lines (Fig. 1-2). These observations suggested the possibility that CH5552074 modulated MITF 
function in melanoma cells. 
 
3.3. MITF protein reduction induced by CH5552074 
To investigate whether inhibiting MITF leads to cell growth inhibition in melanoma cells, 
the effect of MITF siRNAs on MITF inhibition was examined in a cell growth inhibition assay 
in melanoma cells. MITF siRNAs induced the degradation of MITF protein (Fig. 1-3a) and 
MITF mRNA (Fig. 1-3b) at 48 hours. In a further cell growth inhibition assay of SK-MEL-5 
and SK-MEL-30 cells treated with 10 nM of siRNAs for 4 days, cell growth inhibition was 
observed (Fig. 1-3c), which suggests that the cell growth of SK-MEL-5 and SK-MEL-30 cells 
depends on MITF. 
 
3.4. Cell growth inhibition induced by MITF knockdown in SK-MEL-5 cells 
To evaluate the effect of the compound on MITF protein expression, I evaluated MITF 
protein levels in SK-MEL-5 and SK-MEL-30 cells that had been treated with CH5552074 for 
24 hours at doses from 0.01 μM to 10 μM. The western blotting analysis showed that 
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CH5552074 treatment in melanoma cells suppressed MITF expression dose-dependently (Fig. 
1-4a). When MITF expression levels from 6 hours to 48 hours in SK-MEL-5 cells were 
measured, expression levels of MITF increased in a time-dependent manner (Fig. 1-4b). MITF 
expression in SK-MEL-5 cells treated with 10 μM of the compound were suppressed from 24 
hours. At 24 hours, the MITF expression level in the treated cells decreased to 36% that of the 
control cells. To examine whether MITF reduction leads to cell growth inhibition, I evaluated 
real-time cell growth inhibition in SK-MEL-5 cells treated with CH5552074 for 72 hours. Cell 
growth inhibition induced by the compound was observed from around 24 hours after the 
compound was added (Fig. 1-4c). These data support that cell growth inhibition in SK-MEL-5 
cells treated with CH5552074 is correlated with MITF downregulation. 
To support MITF specificity of CH5552074 effect, its activity in cell lines of other tumor 
types without MITF expression was evaluated. First, I determined MITF expression levels in 
the lung cancer cell line NCI-H345 and the colon cancer cell line SW1116. MITF expression 
was observed in melanoma cell lines, but not in NCI-H345 or SW1116 cells (Fig. 1-4d). 
Although CH5552074 showed cell growth inhibition activity in melanoma cells with MITF 
expression (Fig. 1-1b), cell growth inhibition was not observed in NCI-H345 and SW1116 cells 
when they were treated with CH5552074 (Fig. 1-4e), which suggested that CH5552074 
exhibited cell growth inhibition activity in melanoma cells with MITF expression. 
To ascertain whether the reduced MITF protein was induced by inhibited MITF mRNA 
expression, I then measured mRNA expression levels of MITF in cells treated with CH5552074 
for 24 hours. Although MITF protein was reduced by the compound at 24 hours, no change in 
MITF mRNA expression was observed (Fig. 1-4f), which suggested that the reduction in MITF 
protein level induced by CH5552074 was regulated at the protein level, but not at the mRNA 
level.  
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4. Discussion 
 
Although some potent therapeutics, such as trametinib, that were identified in a cell-based 
phenotypic screen have been approved and utilized in clinic [38, 39], the difficulty of 
identifying the target molecule of compounds obtained by this approach remains as a major 
hurdle in drug development. Although the chemical biology approach is commonly used, the 
success rate is not so high. The approach outlined in this paper successfully correlates the 
cellular sensitivity of a newly-identified agent with the mRNA expression profiles to identify 
the target molecule by pathway analysis and then confirms the activity in a western blotting 
analysis. In this study, I identified the mode of action of an anti-melanoma agent, CH5552074, 
which had been selected in a phenotypic screen, by correlating the cellular sensitivity to the 
compound with the mRNA expression profiles in IPA (Table 1-2 and 1-3). The suggestion that 
the MITF pathway may contribute to CH5552074 activity was then confirmed in a western 
blotting and an RT-PCR analysis that showed MITF protein degradation in melanoma cells 
treated with CH5552074 (Fig. 1-4). 
MITF has a critical role in melanoma cell growth and seems to be an attractive molecular 
target for melanoma therapy. Overexpression of MITF protein and gene amplification of MITF 
are observed in melanoma patients [21, 24]. Moreover, when MITF-amplified melanoma cell 
lines are transduced with a dominant-negative MITF mutant, suppression of MITF inhibits 
melanoma cell growth [24]. MITF overexpression is observed in melanomas resistant to BRAF 
inhibitors and a knockdown of MITF restores the activity of a BRAF inhibitor in resistant 
melanoma cells [40]. However, the lack of a catalytic domain in MITF protein makes it difficult 
to obtain inhibitors that directly target MITF protein. 
Because targeting MITF is an attractive strategy for melanoma therapy and overcoming 
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resistance to BRAF inhibitors but is difficult to achieve directly, current research is 
investigating the potential of inhibiting the MITF function indirectly. Chemical inhibition of 
AMP-activated kinase (AMPK) led to a decrease in MITF protein levels [41], and histone 
deacetylase (HDAC) inhibitors suppressed MITF mRNA expression in melanoma cells [42]. 
The human immunodeficiency virus type 1 (HIV1)-protease inhibitor nelfinavir suppressed 
MITF expression through paired box gene 3 (PAX3) inhibition and sensitized melanoma cells 
with BRAF mutation and NRAS mutation to MAPK pathway inhibitors [15]. This study 
contributes to this line of research by finding that CH5552074 reduced expression levels of 
MITF protein and induced cell growth inhibition in melanoma cells. 
To fully understand the potential of the compound as a melanoma therapeutic, the 
mechanisms by which CH5552074 reduces MITF expression need to be investigated. Some 
mechanisms that modulate MITF expression levels have been reported. One example is the 
transcription factor PAX3, which was shown to regulate MITF transcription in melanoma cells 
[43]; however, CH5552074 suppressed MITF expression at the protein level but not at the 
transcription level (Fig. 1-4). In another example, expression levels of MITF were affected by 
mutant BRAF activation of the MAPK pathway and by inhibition of the pathway by BRAF 
inhibitors and MEK inhibitors [32, 44, 45]. To determine whether CH5552074 could affect the 
MAPK pathway, I evaluated its effect on modulating the phosphorylation levels of ERK, but 
no change was observed (data not shown). Further research will investigate the mechanisms by 
which CH5552074 reduces MITF expression to augment the current study. 
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5. Tables 
 
Table 1-1 IC 50 values of CH5552074 and BRAF mutation status in skin cancer cell 
lines. 
Cell lines IC50 (μM) BRAF 
SK-MEL-5 0.24 V600E 
SK-MEL-30 0.30 wt 
A375 0.55 V600E 
SK-MEL-1 0.58 V600E 
SK-MEL-28 0.65 V600E 
A-431 0.96 wt 
SK-MEL-2 0.97 wt 
A2058 1.1 V600E 
HMCB 1.1 wt 
C32 1.2 V600E 
 
Melanoma cells and A-431 cells were incubated for 4 days at 37°C in the presence of serially 
diluted CH5552074. Cell viability was measured with Cell Counting Kit-8 solution. 
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Table 1-2 Gene set with correlation factors analyzed in IPA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R, correlation factor of natural logarithmic expression levels of each probe in microarray 
analysis and natural logarithmic IC50 values in cell lines. 
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Table 1-3 Upstream analysis in IPA 
Upstream 
regulator 
p-value of 
overlap 
Target molecules in dataset 
MITF 8.40E-09 
AIM1, AMDHD2, FGD4, IL6R, ITPKB, MET, MITF, SLC45A2, 
TMC6, TMEM251, TRPM1 
ATN1 2.93E-05 ATP1B1, NEFL, PTPRF, SOCS2, SPP1, TM4SF1 
forskolin 3.42E-05 
ATP1B1, DAB2, GBP1, MET, MITF, NR4A3, OCA2, PDK4, 
PTPRF, SLC45A2, SPP1, TM4SF1 
GSK0660 5.79E-05 PDK4, TRIM63 
TRIM24 7.15E-05 CSRP1, NMI, PLEC, SOCS2, SPP1 
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6. Figures 
 
 
 
 
Fig. 1-1 Cell growth inhibition activity of CH5552074. (a) Chemical structure of CH5552074. 
(b) SK-MEL-5 and SK-MEL-30 cells were incubated for 4 days at 37°C in the presence of 
serially diluted CH5552074. Cell viability was analyzed with Cell Titer-Glo after 96-hour 
incubation. All points indicate the mean ± SD (n = 3). 
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Fig. 1-2 Gene expression levels of MITF, TRPM1, and SLC45A2 in melanoma cell lines.  
Gene expression levels of (a) MITF and (b) TRPM1 and SLC45A2, which are regulated by 
MITF, were measured in a microarray analysis of RNA extracted from in vitro cultivated 
melanoma cell lines and A-431 cells. 
 
 
  
  
23 
 
 
 
 
Fig. 1-3 Cell growth inhibition induced by MITF knockdown in melanoma cells. SK-MEL-
5 cells were transfected with 10 nM of 3 clones of MITF siRNA or control siRNA and incubated 
for 48 hours before measuring (a) MITF protein levels by western blotting, and (b) MITF 
mRNA expression levels by RT-PCR. All points indicate the mean ± SD (n = 3). (c) Cell 
viability was analyzed with Cell Titer-Glo after 96-hour incubation. All points indicate the mean 
± SD (n = 3). 
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Fig. 1-4 MITF protein reduction and cell growth inhibition induced by CH5552074 in 
melanoma cell lines. (a) Western blots show the protein expression levels of MITF in 
melanoma cells that had been treated with the indicated concentrations of CH5552074 for 24 
hours. (b) SK-MEL-5 cells were cultivated for indicated hours with 10 μM of CH5552074. (c) 
In SK-MEL-5 cells incubated for 72 hours at 37°C in the presence of serially diluted 
CH5552074, real-time cell growth was monitored by cell images taken every 4 hours and 
assessed by IncuCyte Zoom System. All points indicate the mean ± SD (n = 3). (d) The 
expression levels of MITF protein in the indicated cell lines were evaluated by western blotting 
analysis. (e) NCI-H345 lung cancer cells and SW1116 colon cancer cells were incubated for 4 
days at 37°C in the presence of serially diluted CH5552074. Cell viability was analyzed with 
Cell Titer-Glo after 96-hour incubation. All points indicate the mean ± SD (n = 3). (f) The 
expression levels of MITF mRNA in SK-MEL-5 cells incubated in the presence of serially 
diluted CH5552074 for 24 hours were analyzed by RT-PCR analysis. All points indicate the 
mean ± SD (n = 3). 
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Chapter II: MITF suppression improves the sensitivity of 
melanoma cells to a BRAF inhibitor 
 
1. Introduction 
 
Malignant melanoma is an aggressive type of cancer that is life-threatening in the advanced 
stage. Approximately 50% of cutaneous melanomas harbor BRAF mutations that cause 
constitutive activation of downstream signaling via the MAPK pathway [5, 46]. Although 
melanoma patients with the BRAF mutations are sensitive to selective BRAF inhibitors and 
combination therapy with MEK inhibitors [6, 27, 28], 50% of patients treated with BRAF 
inhibitors have disease progression approximately 6 months after treatment initiation [7, 8]. 
MITF is a melanocytic lineage-specific transcription factor that regulates the expression of 
various genes essential for melanin synthesis in melanocytes [47]. MITF is frequently expressed 
in melanoma and has a critical role in transformation and progression of melanoma [21, 22]. 
Moreover, genetic amplification of MITF is observed in melanomas, and MITF inhibition by 
dominant-negative MITF reduces cell growth in melanoma cells [13, 24, 48]. These findings 
suggest that MITF is a potential target for melanoma therapy. 
Because targeting MITF directly with small molecules is significantly challenging, a 
potential strategy is pharmacologically inhibiting MITF indirectly. Support for this strategy is 
that HDAC inhibitors suppress MITF mRNA expression in melanoma cells by inhibiting SRY-
related HMG-box 10 (SOX10) expression [42], and that the HIV1-protease inhibitor nelfinavir 
suppresses MITF expression by inhibiting PAX3 and also sensitizes melanoma cells with BRAF 
and NRAS mutations to MAPK pathway inhibitors [15]. Additionally, the MITF suppressor 
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CH5552074, which was previously identified by screening in a melanoma cell panel, was found 
to downregulate MITF protein and induce growth inhibition in melanoma cells [49]. 
In this study, I describe CH6868398, an orally available MITF suppressor derivatized from 
the CH5552074 compound. I evaluated the activity of CH6868398 in vitro and in vivo and, 
moreover, examined the effect of combination treatment with a selective BRAF inhibitor, 
PLX4720. 
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2. Materials and Methods 
 
2.1. Reagents 
CH6868398, CH6813089, and CH6987687 were synthesized at Chugai Pharmaceutical 
Co., Ltd (Kanagawa, Japan). PLX4720 was purchased from Abcam (Cambridge, UK). 
Dharmacon ON-TARGETplus siRNA was purchased from GE Healthcare (Buckinghamshire, 
UK). siRNA transfection was performed with Lipofectamine RNAiMAX reagent (Invitrogen, 
Carlsbad, CA, USA). 
 
2.2. Cell cultures 
SK-MEL-5, SK-MEL-28, and A101D cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). MEL-HO, IPC-298, and SK-MEL-30 cells were obtained 
from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, 
Germany). SK-MEL-5 and SK-MEL-28 cells were maintained in EMEM supplemented with 
10% FBS and 1 mM sodium pyruvate. MEL-HO, IPC-298, and SK-MEL-30 cells were 
maintained in RPMI-1640 supplemented with 10% FBS. A101D cells were maintained in 
DMEM supplemented with 10% FBS and 1 mM sodium pyruvate. 
 
2.3. In vitro cell growth assay 
The cells were seeded onto 96-well plates at 3000 cells/well containing various 
concentrations of the compound and were incubated for 4 days at 37°C. The chemiluminescent 
signal for cell viability was measured with an EnVision Multilabel Plate Reader (PerkinElmer, 
Waltham, MA, USA) after addition of a Cell Titer-Glo luminescence cell viability kit (Promega, 
Madison, WI, USA). Anti-proliferative activity was calculated using the formula (1−T/C) × 
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100 (%), where T represents the measured values of reagent-treated cells and C represents that 
of untreated control cells. 
 
2.4. Western blot analysis 
Cells were seeded in a 6-well plate at 2 x 105 cells/well for single compound treatment or 
3 x 105 cells/well for combination treatment, and were treated with inhibitors or a solvent 
control (0.1% dimethyl sulfoxide (DMSO)) for 2, 6, 24, or 48 hours. For siRNA studies, cells 
were seeded in a 6-well plate at 2 x 105 cells/well and were treated with siRNAs. After siRNA 
treatment for 24 hours, cells were treated with inhibitors or a solvent control (0.1% DMSO) for 
24 hours. Cells were lysed in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, 
USA) containing protease inhibitors and phosphatase inhibitors. Cell lysates were denatured 
with NuPAGE LDS Sample Buffer (Thermo Fisher Scientific, Rockford, IL, USA) with 2-
mercaptoethanol. At least 10 μg of cell lysates were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Western blot analysis was performed as 
described previously [35]. Primary antibodies were used for MITF (Santa Cruz Biotechnology, 
Dallas, TX, USA, #sc-56725), GAPDH (Abcam, #ab201822), phospho-ERK1/2 (Cell 
Signaling Technology, #9101), ERK1/2 (Cell Signaling Technology, #4696 and #9102), cleaved 
PARP (Cell Signaling Technology, #5625), cleaved Caspase 3 (Cell Signaling Technology, 
#9664), and Bim (abcam, #ab32158). Signals were developed using Pierce Western Blotting 
Substrate Plus (Thermo Fischer Scientific) and detected with LAS-4000 (Fujifilm, Tokyo, 
Japan). The bands were quantified by densitometry using ImageQuant TL 1D software (GE 
Healthcare, Little Chalfont, UK) and normalized using the expression levels of GAPDH protein. 
 
2.5. Mouse xenograft studies 
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All animal experiments were performed in accordance with the protocols approved by the 
Institutional Animal Care and Use Committee of Chugai Pharmaceutical Co., Ltd (approval 
number: 12-292). All animals were housed in a specific pathogen-free environment under 
controlled conditions. Chlorinated water and irradiated food were provided ad libitum. The 
health of the mice was monitored daily. A total of 5 x 106 SK-MEL-30 cells/200 μL per mouse 
were subcutaneously injected into the right flank of female BALB/c nu/nu mice (Charles River 
Laboratories, Kanagawa, Japan). Tumor size was measured using a gauge twice a week, and 
tumor volume (TV) was calculated using the following formula: TV = ab2/2, where a is the 
length of the tumor and b is the width. Once the tumors reached a volume of approximately 200 
mm3, mice were randomized into groups (n = 4 in each group), and treatment was initiated. 
Vehicle (10% DMSO, 10% Cremophor EL, 15% polyethylene glycol, and 15% 2-
hydroxypropyl-β-cyclodextrin (HPCD) in distilled water) or CH6868398 was orally 
administered by gavage once daily for 10 days. Tumor growth inhibition (TGI) was calculated 
using the following formula: TGI = (1 – [Tt – T0]/[Ct – C0]) × 100, where T (TV of the treated 
group, T0 on the first day of treatment or Tt on Day t) and C (TV of the control group, C0 on the 
first day of treatment or Ct on Day t) represent mean tumor volume. The maximum tolerated 
dose (MTD) was defined as the dose that resulted in neither lethality nor more than 20% 
bodyweight loss. 
 
2.6. Gene expression analysis with TaqMan probes 
Cells were seeded in a 6-well plate at 2 x 105 cells/well and were treated with inhibitors or 
a solvent control (0.1% DMSO) for 48 hours. Total RNA was isolated from cells with an 
RNeasy Mini Kit (Qiagen, Germantown, MD, USA). For RT-PCR analysis, 200-1,000 ng of 
the isolated RNA and TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Foster City, 
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CA, USA) were used. The following TaqMan probes (Applied Biosystems) were used: 
SLC45A2 (Hs01125486_m1), TRPM1 (Hs00931865_m1), and GAPDH (4325792). Reactions 
were run on a ViiA 7 Real-Time PCR System (Applied Biosystems) with 40 amplification 
cycles. The gene expression levels were measured against the housekeeper gene GAPDH and 
determined utilizing ViiA 7 software (Applied Biosystems). 
 
2.7. Statistical analysis 
Statistical analyses were performed using JMP version 11.2.1 software (SAS Institute, Cary, 
NC, USA). Statistical significance was determined by Dunnett’s test, Student’s t-test, or 
Tukey’s test and is shown in the figure legends. P < 0.05 was considered to indicate a 
statistically significant result. Significant p values are labeled with asterisks: *, p < 0.05; **, p 
< 0.01; ***, p < 0.001. 
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3. Results 
 
3.1. Identification of CH6868398 and its activity on cell growth inhibition 
To obtain an orally available anti-melanoma drug, I derivatized MITF suppressor 
CH5552074, which had been identified in a screening for compounds in a melanoma cell panel 
[49], and identified CH6813089 (Fig. 2-1a). Because CH6813089 is a racemic mixture of 
CH6868398 and CH6987687, I evaluated the activity of each of the three compounds in SK-
MEL-5 cells, which are sensitive to siRNAs against MITF (Fig. 2-2). In the cell growth 
inhibition assay, CH6813089 and CH6868398 were more potent than CH6987687 (Fig. 2-1b), 
which suggested that CH6868398 was the active compound included in CH6813089. When 
MITF suppression activity of CH6868398 and CH6987687 in SK-MEL-5 cells was examined, 
MITF expression levels significantly decreased in the cells treated with CH6868398 (Fig. 2-
1c). 
 
3.2. CH6868398 activity on cell growth inhibition and MITF suppression in melanomas 
To further evaluate cell growth inhibition by CH6868398 in melanoma cells, I utilized 6 
melanoma cell lines with different BRAF mutation status: BRAF V600E mutation (MEL-HO, 
SK-MEL-5, SK-MEL-28, and A101D cells) and wild-type BRAF (IPC-298 and SK-MEL-30 
cells). First, I examined MITF expression and whether cell growth depended on MITF 
expression in the melanoma cell lines. MITF expression was observed in MEL-HO, SK-MEL-
5, SK-MEL-28, IPC-298, and SK-MEL-30 cells, but not in A101D cells (Fig. 2-3a). When I 
treated the melanoma cells with 3 individual siRNAs against MITF, cell proliferation of the 
melanoma cells with MITF expression was inhibited by 3 siRNAs against MITF (Fig. 2-2). 
Then I assessed the cell growth inhibition activity of CH6868398 in melanoma cells with and 
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without MITF expression. CH6868398 showed significant cell growth inhibition activity 
against MEL-HO, SK-MEL-5, SK-MEL-28, IPC-298, and SK-MEL-30 cells which had MITF 
expression and growth dependence on MITF, but not against A101D cells which had no MITF 
expression (Fig. 2-3b). This cell growth inhibition activity was not related to BRAF mutation 
status and did not correlate to MITF protein expression levels, but was related to sensitivity to 
MITF siRNAs (Fig. 2). To confirm the anti-tumor activity of CH6868398 against melanomas, 
I evaluated in vivo efficacy of the compound in a SK-MEL-30 xenograft mouse model. Daily 
oral administration of CH6868398 at MTD, 50 mg/kg, resulted in significant anti-tumor activity 
in the SK-MEL-30 model with a maximum TGI of 78% at Day 32 (Fig. 2-3c). In the in vivo 
efficacy study, the doses of CH6868398 tested were well tolerated without body weight loss, 
change in food intake, and death. 
Next, to confirm whether CH6868398 suppressed MITF in CH6868398-sensitive 
melanoma cells, I treated melanoma cells with CH6868398 for 24 hours at doses from 0.01 μM 
to 10 μM, and found that MITF expression was suppressed by CH6868398 dose-dependently 
and was significantly downregulated with 10 μM of CH6868398 (Fig. 2-4a). Although mutated 
BRAF plays a critical role in regulating MITF expression [32], CH6868398 suppressed MITF 
expression not only in melanoma cells with BRAF mutation but also in those without BRAF 
mutation. When I measured MITF expression levels from 6 to 48 hours in melanoma cells 
treated with 10 μM of CH6868398, expression levels of MITF were significantly suppressed 
from 6 hours in SK-MEL-5 cells and from 24 hours in SK-MEL-30 cells (Fig. 2-4b). To address 
inhibition of the MITF function, I assessed the mRNA expression levels of SLC45A2 and 
TRPM1, which are regulated by MITF [36, 37], in melanoma cells treated with CH686838, and 
observed that CH6868398 significantly decreased these expression levels (Fig. 2-4c). These 
observations suggested that CH6868398 suppressed the MITF function and inhibited the cell 
  
34 
 
growth in melanoma cells. 
 
3.3. Enhancement of cell growth inhibition activity of a BRAF inhibitor in combination 
with CH6868398 in melanoma cells with BRAF mutation 
Because treatment with a selective BRAF inhibitor is standard therapy for melanoma 
patients with the BRAF mutations, I assessed the possible contribution of CH6868398 to 
selective BRAF inhibitor treatment in melanoma cells. First, I examined melanoma cell 
sensitivity to the BRAF inhibitor PLX4720, and found that PLX4720 dose-dependently 
inhibited cell growth in MEL-HO, SK-MEL-5, SK-MEL-28, and A101D cells (Fig. 2-5a). 
When I evaluated the expression levels of phospho-ERK in melanoma cells treated with 
PLX4720, PLX4720 decreased phospho-ERK levels (Fig. 2-5b). Then I analyzed MITF 
expression levels in melanoma cells treated with PLX4720, and found that the expression level 
of MITF protein was significantly decreased by PLX4720 treatment in SK-MEL-28 and MEL-
HO cells, but not inhibited in SK-MEL-5 cells (Fig. 2-5b). 
Because PLX4720 treatment did not suppress MITF expression levels in SK-MEL-5 cells, 
I confirmed whether MITF inhibition by CH6868398 enhances the cell growth inhibition 
activity of a BRAF inhibitor. To do this, I compared cell growth inhibition in melanoma cell 
lines by CH6868398 and/or PLX4720 treatment. In single agent treatment, PLX4720 showed 
more potent cell growth inhibition activity than CH6868398 in MEL-HO and SK-MEL-28 cells, 
but not in SK-MEL-5 cells (Fig. 2-6a). Compared with PLX4720 treatment, combination 
treatment of CH6868398 and PLX4720 showed more potent cell growth inhibition activity and 
significantly suppressed MITF expression levels in MEL-HO and SK-MEL-5 cells (Fig. 2-6a-
b). This result indicated that MITF inhibition by CH6868398 enhanced the cell growth 
inhibition activity of PLX4720. To understand the mechanism of the CH6868398 and PLX4720 
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combination, I evaluated apoptosis induction after combination treatment. Combination 
treatment of CH6868398 and PLX4720 resulted in significantly enhanced levels of cleaved 
PARP and cleaved Caspase 3 in melanoma cells (Fig. 2-6b). Phosphorylation levels of ERK 
were not changed by combination treatment compared with PLX4720 treatment. When I 
evaluated the expression levels of Bim in melanoma cells treated with CH6868398 and 
PLX4720, combination treatment for 24 hours significantly induced Bim expression (Fig. 2-
6c). These results suggest that CH6868398 is a potential combination partner for BRAF 
inhibitors in melanomas with BRAF mutations. Finally, to confirm that the combination effect 
of CH6868398 and PLX4720 was achieved through MITF suppression by CH6868398, the 
combination effect of PLX4720 and siRNAs against MITF was evaluated. As expected, MITF 
suppression by siRNAs significantly enhanced the levels of cleaved PARP and cleaved Caspase 
3 induced by PLX4720 in SK-MEL-5 cells (Fig. 2-6d), which suggested that MITF suppression 
is a potential option for combination treatment with BRAF inhibitors in melanomas. 
 
 
  
  
36 
 
4. Discussion 
 
MITF is an attractive target for melanoma treatment due to its oncogenic activity in 
melanomas. Gene amplification of MITF was observed in up to 20% of melanomas, and MITF 
inhibition by dominant-negative MITF resulted in cell growth inhibition in MITF-amplified 
melanoma cells [24, 50, 51]. Melanoma cell lines had elevated levels of MITF and were 
dependent on MITF activity for cell proliferation (Fig. 2-2). Moreover, indirect pharmacologic 
inhibition of MITF led to cell growth inhibition in melanoma cells [15, 42]. I also identified the 
MITF suppressor CH5552074 in a melanoma cell panel screen of a chemical library [49], and 
then generated an orally available MITF suppressor, CH6868398. The compound showed not 
only in vitro cell growth inhibition activity, but also in vivo efficacy in a SK-MEL-30 melanoma 
xenograft model without significant body weight loss (Fig. 2-3). 
MITF expression is upregulated by MAPK pathway activation and can be modulated in 
melanomas by treatment with a MAPK pathway inhibitor. In melanoma cells, mutated BRAF 
upregulated MITF transcription by activating the MAPK pathway [32]. However, the 
relationship of MAPK pathway activation and MITF expression level is complex because 
activation of MAPK pathway also induces MITF degradation [52]. In melanoma cell lines with 
BRAF mutation, PLX4720 treatment significantly suppressed MITF expression in MEL-HO 
and SK-MEL-28 cells, but not in SK-MEL-5 cells (Fig. 2-5b). Although MITF expression 
levels after PLX4720 treatment are inconsistent among these melanoma cell lines, their cell 
growth activity is dependent on MITF (Fig. 2-2). Moreover, overexpression of MITF was 
observed in the early phase of resistance to BRAF inhibitors, and its suppression by siRNA 
inhibited cell proliferation in melanoma cells [15]. In clinic, overexpression of MITF through 
gene amplification was observed in melanomas that relapsed after BRAF inhibitor treatment 
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[13]. These observations suggested the idea that MITF inhibition by CH6868398 would 
enhance the cell growth inhibition activity of MAPK pathway inhibitors. 
BRAF inhibitors are standard treatment for melanoma patients with BRAF mutations. 
Although the BRAF inhibitor PLX4720 exhibited cell growth inhibition activity to melanoma 
cell lines with BRAF mutation, MITF expression was still observed in the melanoma cells after 
PLX4720 treatment (Fig. 2-5), which suggests that MITF suppression by CH6868398 would 
lead to additional cell proliferation inhibition. CH6868398 treatment significantly suppressed 
MITF expression levels and cell growth in MEL-HO and SK-MEL-5 cells and induced 
apoptosis in the melanoma cells when the treatment was combined with PLX4720 treatment 
(Fig. 2-6a-c). Additional evaluation such as in vivo efficacy studies are required to confirm the 
potential of this compound as a therapeutic against melanomas with BRAF mutations. 
PLX4720 is an analogue of vemurafenib which is widely used in clinic as a BRAF inhibitor 
for melanomas with BRAF mutation. The IC50s of PLX4720 and vemurafenib on enzyme 
activity of BRAF V600E are 13 nM and 30 nM, respectively [53, 54]. The pharmacokinetics of 
vemurafenib used in clinic show that after continuous twice-daily dosing of 960 mg for 15 days 
mean plasma concentration remained stable and was about 100 μM [55, 56]. From this I can 
assume that the PLX4720 concentration (10 μM) seen in these combination studies with 
CH6868398 is reasonable. 
CH6868398 treatment suppressed MITF protein in melanoma cell lines, but the mechanism 
of MITF protein suppression is still unclear. MITF expression is regulated by MAPK pathway 
activation, such as mutant BRAF activation, and is inhibited by BRAF inhibitors in some 
melanoma cell lines that have the BRAF mutation. A BRAF inhibitor inhibited phosphorylation 
of ERK in BRAF-mutant melanoma cells, but CH6868398 did not (Fig. 2-6b). In another 
example that may illustrate the cause of MITF suppression, the HIV-protease inhibitor 
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nelfinavir suppresses MITF expression by inhibiting PAX3, which is a transcription factor 
regulating MITF expression [15]. Nelfinavir treatment inhibits MITF mRNA expression, but 
CH6868398 did not suppress MITF mRNA in melanoma cells (Fig. 2-7). Determining the 
mechanisms of different effects on MITF suppression by CH6868398 is an important future 
task and will reveal the potential of the compound in melanoma therapy. 
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5. Figures 
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Fig. 2-1 CH6868398 activity on cell growth inhibition and MITF suppression. (a) Chemical 
structures of CH6813089, CH6868398, and CH6987687.  (b) Cell growth inhibition activity 
of CH6813089, CH6868398, and CH6987687 in SK-MEL-5 cells. SK-MEL-5 cells were 
incubated for 4 days at 37°C in the presence of serially diluted compounds. Cell viability was 
analyzed with Cell Titer-Glo. All points indicate the mean ± SD (n = 3). (c) CH6868398 
suppression of MITF in SK-MEL-5 cells. Melanoma cells were treated with the indicated 
concentrations of CH6868398 or CH6987687 for 24 hours. MITF protein levels were 
determined by western blotting (left) and densitometry analysis of the blots (right). The results 
shown are representative of the three independent experiments. Dunnett’s test: compared with 
DMSO group. 
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Fig. 2-2 MITF dependency of melanoma cell lines. Melanoma cells were transfected with 10 
nM of 3 individual siRNAs against MITF or control siRNA and incubated for 4 days. Cell 
viability was analyzed with Cell Titer-Glo. All points indicate the mean ± SD (n = 3). Statistical 
significance compared with No siRNA group was examined using Dunnett’s test. 
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Fig. 2-3 Anti-tumor activity of CH6868398 in melanoma cells. (a) MITF protein expression 
levels in the melanoma cells, examined by western blotting. (b) Cell growth inhibition activity 
of CH6868398 in melanoma cell lines. The melanoma cell lines were incubated for 4 days at 
37°C in the presence of serially diluted compounds. Cell viability was analyzed with Cell Titer-
Glo. All points indicate the mean ± SD (n = 3). Student’s t-test: compared with DMSO control 
group. N.S., not significant. (c) Efficacy of CH6868398 in a SK-MEL-30 melanoma xenograft 
model (n = 4). Mice inoculated with SK-MEL-30 cells were treated with CH6868398 orally 
once daily for 10 days at the indicated doses. Tumor volume in each group was measured. Data 
were shown as mean + SD. Dunnett’s test: compared with vehicle treatment group at the final 
day.   
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Fig. 2-4 MITF suppression activity of CH6868398 in melanoma cells. (a) MITF suppression 
activity of CH6868398 in melanoma cells. Melanoma cells were treated with the indicated 
concentrations of CH6868398 for 24 hours. MITF protein levels were determined by western 
blotting (left) and densitometry analysis of the blots (right). The blot data shown are 
representative of the three independent experiments. Student’s t-test: compared with DMSO 
treatment group. (b) Time course effects of CH6868398 on MITF suppression. The melanoma 
cell lines were cultivated for indicated hours with 10 μM of CH6868398 (left). The relative 
band intensities of MITF were quantified by densitometry (right). The blot data shown are 
representative of the three independent experiments. Student’s t-test: compared with DMSO 
treatment group. (c) mRNA expression levels in the melanoma cells treated with 10 μM of 
CH6868398. mRNA expression levels were determined by RT-PCR analysis of the melanoma 
cells treated with the compound for 48 hours. All points indicate the mean ± SD (n = 3). 
Student’s t-test: compared with DMSO treatment group. 
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Fig. 2-5 Effect of PLX4720 on MITF expression and cell growth inhibition in melanoma 
cells. (a) Cell growth inhibition activity of PLX4720. The melanoma cell lines were incubated 
for 4 days at 37°C in the presence of serially diluted compounds. Cell viability was determined 
with Cell Titer-Glo. All points indicate the mean ± SD (n = 3). (b) Expression levels of phospho-
ERK and MITF in melanoma cells treated with PLX4720. The melanoma cell lines with BRAF 
mutation were cultivated for 24 hours with 10 μM of PLX4720. The protein expression levels 
were examined by western blotting (top) and by densitometry (bottom). The blot data shown 
are representative of the three independent experiments. Student’s t-test: compared with DMSO 
treatment group.  
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Fig. 2-6 Combination effect of CH6868398 and PLX4720. (a) Cell growth inhibition activity 
of CH6868398 in combination with PLX4720. The melanoma cell lines were treated with 10 
μM of CH6868398 and/or 10 μM of PLX4720 for 4 days. Cell viability was detected with Cell 
Titer-Glo. All points indicate the mean ± SD (n = 3). Statistical significance was determined 
using Tukey’s test.  (b) MITF suppression and apoptosis induction activity of CH6868398 in 
combination with PLX4720. The melanoma cell lines were cultivated for 24 hours with 10 μM 
of CH6868398 and/or 10 μM of PLX4720. The protein expression levels were detected using 
western blotting (top) and quantified by densitometry (bottom). The blot data shown are 
representative of the three independent experiments. Dunnett’s test: compared with 
combination treatment group. (c) Bim induction activity of CH6868398 in combination with 
PLX4720. The melanoma cell lines were cultivated for indicated hours with 10 μM of 
CH6868398 and PLX4720 (top). The relative band intensities of Bim were determined by 
densitometry (bottom). The blot data shown are representative of the three independent 
experiments. Dunnett’s test: compared with 0 hr group. (d) Apoptosis induction by BRAF 
inhibition and MITF suppression. SK-MEL-5 cells were cultivated for 24 hours with 10 μM of 
PLX4720 24 hours after treatment with 3 individual siRNAs against MITF (top). The relative 
band intensities were quantified by densitometry (bottom). The blot data shown are 
representative of the three independent experiments. Student’s t-test: compared with DMSO 
treatment group. 
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Fig. 2-7 MITF mRNA levels in cells treated with CH6868398. SK-MEL-5 and SK-MEL-28 
cells were treated with the indicated concentrations of CH6868398 for 24 hours. MITF mRNA 
levels were determined by RT-PCR analysis. TaqMan probes for MITF and GAPDH were used. 
All points indicate the mean ± SD (n = 3). All groups compared with control group were not 
significant in Dunnett’s test. 
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General Discussion 
 
Melanoma treatment with BRAF inhibitors and immune checkpoint inhibitors significantly 
improves response rate and overall survival, but a subset of melanoma patients is still 
insensitive to these therapeutics. For such patients, a novel anti-melanoma agent with other 
action mechanisms is required. 
Chapter I describes how I initially screened a small molecule compound library to identify 
compounds that inhibited the growth of melanoma cells using a melanoma cell panel [49]. One 
of the screening methods in drug discovery is target-based screening. When 15 first-in-class 
oncologic drugs approved between 1999 and 2013 were examined, it was found that 11 (73%) 
originated from target-based screens [38]. Target-based screens have been actively conducted 
in our laboratory. Specific inhibitors, such as an FGFR inhibitor and an ALK inhibitor, have 
been identified [57, 58]. One of the advantages of a target-based screening system is that 
millions of drug-like molecules in a chemical library are screened in a few months. Therefore, 
target-based screens are powerful screening systems for identification of hit compounds when 
critical target molecules are reported or identified. However, no promising target molecules 
which inhibition leads to tumor growth arrest have not been identified for malignant melanoma, 
except for mutated BRAF. Therefore, I selected a cell-based phenotypic screen for the 
identification of anti-melanoma agents. 
One of the major hurdles in cell-based phenotypic screens in drug development is the 
identification of action mechanisms of hit compounds. For the identification of binding 
molecules to the hit compounds, a chemical biology approach is one of the effective strategies. 
One successful example for the identification of a binding molecule is the MEK inhibitor, JTP-
70902. A target molecule of JTP-70902, which was identified as a p15INK4b mRNA inducer in 
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a cell-based phenotypic screen, was successfully identified as MEK1/2 by compound-
immobilized affinity chromatography [39]. A key factor for success in the identification of the 
target molecule using a chemical biology approach is the potent activity of JTP-70902. 
Treatment with 10 nM of JTP-70902 induces p15INK4b expression, cell cycle arrest, and 
phosphorylation inhibition of ERK1/2 [39]. In contrast, IC50 values for cell growth inhibition 
of CH5552074 are greater than 100 nM (Table 1-1), and so, the chemical biology approach is 
not suitable for the identification of target molecules of CH5552074. Accordingly, IPA analysis 
is conducted for action mechanism examination. 
IPA upstream analysis can suggest upstream factors that can affect the expression profile 
of dataset genes. In order to utilize IPA upstream analysis, I initially selected dataset genes, 
which were differentially expressed in CH5552074-sensitive skin cancer cell lines and 
CH5552074-insensitive cell lines (Table 1-2), and then the dataset genes were analyzed in IPA 
upstream analysis. The analysis suggested that MITF might regulate the expression levels of 
dataset genes (Table 1-3). To confirm the suggestion, western blotting analysis of MITF in the 
melanoma cells treated with CH5552074 was conducted. This assay showed that CH5552074 
suppressed MITF expression (Fig. 1-4). A key success factor of this analysis is using the dataset 
genes generated from the gene expression data and the CH5552074 sensitivity data only of skin 
cancer cell lines because MITF is specifically expressed in melanoma. Actually, although I 
conducted the same analysis with dataset genes for cell lines in other tumor types, MITF was 
not suggested. This analysis may be a potential option for exploring the mechanism of action 
of a compound obtained in cell-based phenotypic screens. 
Chapter II describes the effect of the combination of a BRAF inhibitor and an MITF 
suppressor, CH6868398. BRAF inhibitor monotherapy is effective against metastatic 
melanoma with BRAF mutation, but the progression-free survival was approximately 6 months 
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after treatment initiation [7, 8]. In order to improve the efficacy of BRAF inhibitors in patients 
with BRAF-mutated melanoma, combination treatment with MEK inhibitors has been 
examined in the clinic. As a result, progression-free survival was improved to 11.0 months in 
the COMBI-d study [59] and 11.4 months in the COMBI-v study in patients treated with a 
combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor [60]; it was 
extended to 9.9 months in patients receiving combined treatment of vemurafenib, a BRAF 
inhibitor, and cobimetinib, a MEK inhibitor [28]. For further improvement of the efficacy of 
combination treatment with BRAF inhibitors, combination treatment of BRAF inhibitors with 
immune checkpoint inhibitors has been evaluated in early phase trials, which suggest that 
potential combination partners of BRAF inhibitors are still required. 
In this study, it was found that melanoma cells still expressed MITF after BRAF inhibitor 
treatment (Fig. 2-5b). In such melanoma cases, additional MITF suppression by CH6868398 
treatment would enhance cell growth inhibition effect. To confirm this possibility, MEL-HO 
and SK-MEL-5 cells were treated with PLX4720 and CH6868398, and as expected, additional 
MITF suppression and cell growth inhibition were observed (Fig. 2-6a-b). Moreover, 
combination treatment of PLX4720 and CH6868398 induced apoptosis in MEL-HO and SK-
MEL cells (Fig. 2-6b-c). These results suggest that CH6868398 for MITF suppression is a 
potential combination partner with BRAF inhibitors in melanoma. 
Focal genomic amplification of MITF is observed in melanoma cells resistant to BRAF 
inhibitors [13]. MITF overexpression is also found in BRAF inhibitor-resistant cell line models 
[15, 61] . In these models, MITF suppression leads to cell growth inhibition or delays drug 
resistance. Drug resistance to BRAF inhibitor is one of the critical issues in melanoma treatment. 
Therefore, further studies of CH6868398 with BRAF inhibitor-resistant models could address 
the issue of BRAF inhibitor resistance. 
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Finally, CH6868398 suppresses MITF activity and inhibits growth inhibition of melanoma 
cells (Fig. 2-3-4). Moreover, it showed anti-tumor activity in an in vivo melanoma xenograft 
model (Fig. 2-3c). Although MITF is a critical factor for proliferation of melanoma cells (Fig. 
2-2), there are only a few reports on indirect MITF inhibitors [15, 41, 42]. Additional 
examination of action mechanisms of MITF suppression by CH6868398 is required, but the 
compound is a potential anti-melanoma therapeutic.  
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